Nipah Virus: Pathogenesis, Transmission Dynamics, and Zoonotic Potential
Introduction
Nipah virus (NiV) is a highly pathogenic paramyxovirus of the genus Henipavirus within the family Paramyxoviridae. First identified in 1998 during a major outbreak of encephalitis and respiratory disease in Malaysian pigs and humans, NiV has since caused recurrent spillovers in Bangladesh, India, and other regions of South and Southeast Asia [1, 2, 3]. The virus is classified as a Biosafety Level 4 (BSL-4) agent due to its high lethality, potential for human-to-human transmission, and lack of approved medical countermeasures. This article examines NiV from a veterinary and zoonotic perspective, detailing its molecular virology, bat reservoir dynamics, transmission to pigs and other livestock, pathogenesis in susceptible animal models, and the diagnostic and intervention strategies relevant to veterinary practice and public health preparedness.
The genus Henipavirus also includes Hendra virus (HeV), Cedar virus, and the recently characterized Ghana virus [4, 5]. HeV and NiV share a common evolutionary origin in pteropid fruit bats and overlap in geographic distribution and ecological niches. Repeated spillover events underscore the virus's pandemic potential and the urgent need for cross-species surveillance and vaccine development [6, 7].
Molecular Virology and Host Cell Entry
NiV is an enveloped virus with a nonsegmented negative-sense RNA genome of approximately 18.2 kb. The genome encodes six structural proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), fusion glycoprotein (F), receptor-binding glycoprotein (G), and large polymerase (L). Additionally, the P gene encodes accessory proteins V, W, and C through RNA editing, which function as interferon antagonists [44].
Receptor Binding and Membrane Fusion
Viral entry is mediated by the receptor-binding protein G and the fusion protein F. The G protein binds to ephrin-B2 and ephrin-B3 receptors, which are highly conserved cell surface molecules expressed on neurons, endothelial cells, and smooth muscle cells [8]. Ephrin-B2 binding triggers conformational changes in G that destabilize the metastable prefusion form of F, leading to its refolding into a trimeric hairpin structure that drives membrane fusion.
Recent cryo-electron microscopy studies of assembled henipavirus nucleoproteins have revealed open and closed conformations of the N protein, suggesting a structural basis for genome access during transcription and replication [9]. The fusion protein contains a conserved N-glycosylation site that stabilizes the prefusion conformation and is critical for receptor engagement [8]. Functional and antigenic constraints on the NiV F protein have been mapped, identifying epitopes that are conserved across henipaviruses and represent targets for cross-neutralizing antibodies [10].
Matrix Protein and Immune Evasion
The NiV matrix protein (M) plays a central role in viral assembly and budding. Additionally, M protein promotes NF-kB activation by targeting multiple signaling modulators, contributing to the inflammatory response observed during infection [11]. The V and W proteins block interferon signaling by inhibiting STAT1 and STAT2 phosphorylation, while the C protein suppresses interferon induction [44]. NSUN2-mediated epitranscriptomic modification of the M protein further modulates ubiquitination and stability, revealing a dual-targeting antiviral strategy [12].
Viral Replication and Cytopathology
NiV replicates efficiently in endothelial cells, epithelial cells, and macrophages. In the African green monkey model, macrophages and dendritic cells are early targets that facilitate viral dissemination to distant organs including the central nervous system (CNS) [13]. Infected endothelial cells become syncytial due to F protein-mediated cell-cell fusion, leading to vasculitis, thrombosis, and parenchymal necrosis. Replication in neurons occurs via axonal transport, enabling direct spread to the brainstem and cerebrum.
Bat Reservoir Dynamics and Spillover Ecology
Pteropid fruit bats (family Pteropodidae) are the primary reservoir hosts for NiV. Infection in bats is largely asymptomatic, presumably due to coevolutionary adaptation. Bats excrete virus in urine, saliva, and feces, contaminating fruit and date palm sap, which serves as the main vehicle for zoonotic spillover [14, 15]. In Bangladesh, seasonal outbreaks are epidemiologically linked to raw date palm sap consumption, with viral transmission amplified by social media promotion of traditional sap collection practices [14].
Ecological vaccination strategies have been proposed to reduce viral shedding from bat populations, including oral vaccines delivered via bait formulations [15]. The superspreading potential of NiV disease, despite self-limited human-to-human transmission in community settings, has been modeled to estimate outbreak risk and control thresholds [16]. Post-mortem surveillance of humans and livestock is also advocated as an innovative strategy for early detection and containment [45].
Geographic Strain Diversity
Two major genetic lineages of NiV have been described: the Malaysia genotype (NiV-MY) and the Bangladesh genotype (NiV-BD). These strains differ in pathogenicity and clinical presentation. In IFNAR knockout mice, NiV-MY causes predominantly respiratory disease, whereas NiV-BD produces more pronounced neurological signs [17]. The Bangladesh strain also appears to have a higher frequency of human-to-human transmission [2]. Geodispersal analysis of NiV strains from Bangladesh reveals multiple independent introductions from bat populations, indicating continuous spillover pressure rather than a single persistent human lineage [18].
Transmission to Pigs and Livestock
Pigs serve as the primary amplifying host in the Malaysian outbreak scenario. The virus is transmitted horizontally among pigs via respiratory droplets, saliva, urine, and feces. Clinically, pigs may develop a febrile, respiratory syndrome characterized by coughing and nasal discharge, with occasional neurological signs such as head pressing and ataxia. Subclinical infections are common in weaned piglets, contributing to undetected viral circulation. The high density of pigs in commercial operations facilitates rapid spread, and infected pigs can shed virus for up to two weeks.
Transmission from pigs to humans occurs via direct contact with infected tissues or respiratory secretions. In Bangladesh and India, where pig husbandry is less intensive, spillover occurs primarily through bat-to-human or bat-to-pig-to-human pathways. The role of other livestock (goats, cattle) as potential intermediate hosts remains under investigation, although experimental infections have not shown high susceptibility.
Pathogenesis in Susceptible Animal Models
The pathogenesis of NiV has been studied in several animal models, including Syrian hamsters, African green monkeys, ferrets, and IFNAR knockout mice. These models recapitulate key features of human disease: acute respiratory distress syndrome, encephalitis, and systemic vasculitis.
Hamster Model
Syrian hamsters (Mesocricetus auratus) develop lethal disease following intranasal or intraperitoneal inoculation. The nucleoside analog 4'-fluorouridine (4'-FlU) has been shown to protect hamsters from lethal NiV challenge when administered prophylactically or therapeutically [19]. Hamsters are also used to evaluate repurposed clinical candidates for NiV and HeV [20].
Nonhuman Primates
African green monkeys (Chlorocebus aethiops) are considered the gold standard model for human disease. Infection recapitulates the full spectrum of disease, including severe respiratory distress and encephalitis. Macrophages and dendritic cells play a critical role in early virus dissemination, with virus detected in the spleen, lymph nodes, and lungs as early as day 2 postinoculation [13]. Heterologous sequential mRNA vaccination of Indian rhesus macaques elicits broad binding and neutralizing antibody responses against diverse henipaviruses, demonstrating the feasibility of pan-henipavirus vaccines [21].
Airway Organoids
Human airway organoids have been successfully employed as a BSL-4 model to study NiV replication and pathogenesis, providing a physiologically relevant system to investigate host-virus interactions and test antiviral compounds [22].
Neurological Pathogenesis
NiV is highly neurotropic. The virus enters the CNS either via the olfactory nerve after intranasal inoculation or through infected circulating monocytes/macrophages crossing the blood-brain barrier. Once inside the CNS, NiV infects neurons, microglia, and endothelial cells, leading to widespread encephalitis, microinfarctions, and neuronal necrosis [23]. The matrix protein's ability to activate NF-kB likely exacerbates neuroinflammation [11]. Persistent T cell immunity following NiV infection has been documented in Malaysian survivors, indicating that long-term antiviral immune responses can be generated [46].
Immune Responses and Cross-Protection
Humoral Immunity
Neutralizing antibodies targeting the G and F glycoproteins are the primary correlate of protection. Cocktails of human monoclonal antibodies (mAbs) targeting both the henipavirus fusion and receptor-binding proteins provide cross-species neutralization [24]. Monomeric and tetrameric forms of the NiV G glycoprotein-based vaccine candidates both elicit robust antibody responses [25]. A linear epitope on the F protein is recognized by sera from human survivors and may serve as a serological marker [26].
Mucosal and Intranasal Vaccination
Intranasal vaccination with bacteriophage T4 coupled with NiV G or F protein induces complete protection against lethal NiV challenge, likely due to mucosal IgA responses [27]. Structural studies have guided the design of a prefusion-stabilized F protein used in a phase 1 mRNA vaccine trial [28].
Cellular Immunity
T cell responses, particularly CD8+ T cells, are important for viral clearance. Persistent T cell immunity has been observed in survivors [46]. Recombinant Cedar virus (rCV) infection of African green monkeys provides cross-protection against NiV and HeV challenge, indicating that nonpathogenic henipaviruses could be developed as live-attenuated vaccine platforms [29].
Diagnostics
Molecular Detection
Real-time reverse-transcription PCR (RT-qPCR) is the primary diagnostic method for acute NiV infection. A rapid field-ready protocol using whole blood and respiratory swabs has been validated for use in resource-limited settings [30]. A one-pot RT-RAA/CRISPR-Cas13a assay has been developed for rapid genotyping of NiV in pigs, enabling differentiation between NiV-MY and NiV-BD [31].
Serology
Enzyme-linked immunosorbent assays (ELISAs) targeting the G glycoprotein are used for serosurveillance in bats, pigs, and humans. A hybrid alphavirus-NiV pseudovirion system has been developed for rapid quantification of vaccine-induced neutralizing antibodies without requiring BSL-4 containment [32].
Antigen Detection
Nipah virus matrix protein (NiV-M) can be detected by immunohistochemistry or antigen capture ELISA in tissue homogenates. Chemical inactivation protocols for henipavirus-infected tissue samples have been validated to permit safe handling in low-containment laboratories [33].
Decision Tree for Diagnostic Workflow
A structured approach for suspect NiV cases in swine is shown below.
flowchart TD
A[Clinical Suspicion: Respiratory or neurological signs in pigs], > B{Recent contact with bats?}
B, >|Yes| C[Collect nasal swabs, whole blood, and tissue samples]
B, >|No| D[Rule out endemic swine diseases: PRRS, influenza, Aujeszky]
C, > E[Rapid RT-qPCR or CRISPR-Cas13a assay]
E, > F{Positive for NiV?}
F, >|Yes| G[Confirm with sequencing or virus isolation]
F, >|No| H[Consider other diagnoses]
G, > I[Implement quarantine, culling, and biosecurity; notify veterinary authorities]
H, > D
Vaccines and Therapeutics
Candidate Vaccines
Several vaccine platforms are under development, including mRNA vaccines, viral vector-based vaccines, subunit vaccines, and virus-like particle vaccines. A phase 1 trial of a structure-based mRNA vaccine encoding the prefusion-stabilized F protein has reported safety and immunogenicity in healthy adults [28]. An intranasal bacteriophage T4-based vaccine shows promise for mucosal delivery [27]. A heterologous sequential mRNA vaccination regimen in monkeys elicits broad binding and neutralizing antibodies against diverse henipaviruses [21].
Monoclonal Antibodies
Human mAb cocktails targeting both F and G provide cross-species neutralization and are being evaluated for postexposure prophylaxis [24, 34]. Modeling studies have informed optimal deployment strategies for NiV vaccines and monoclonal antibodies, including ring vaccination and targeted administration [35].
Antiviral Agents
The nucleoside analog 4'-fluorouridine (4'-FlU) is a potent inhibitor of NiV in hamsters [19]. Repurposing of FDA-approved drugs using a recombinant Cedar virus surrogate identified several candidates, including favipiravir and remdesivir, which reduce viral replication in vitro [36]. A high-throughput screen of clinical candidates has been conducted against both NiV and HeV [20]. In silico AI-driven studies have predicted the antiviral potential of phytochemicals from selected medicinal plants [37].
Zoonotic Potential and One Health Implications
NiV is a paradigm for bat-origin zoonoses with pandemic potential. The virus's broad host range, ability to use conserved ephrin receptors, and capacity for human-to-human transmission make it a high-priority emerging pathogen. Drivers of spillover include deforestation, agricultural encroachment into bat habitats, and cultural practices such as date palm sap consumption [2, 14]. Understanding these drivers is essential for developing prevention strategies, including ecological vaccination of bats [15] and behavioral interventions [38, 14].
The veterinary community plays a critical role in early detection and containment. Surveillance of pigs, horses, and other livestock for NiV antibodies and viral RNA can provide an early warning system for impending outbreaks. Post-mortem surveillance in humans and animals is an underutilized but promising approach for detecting cryptic transmission chains [45].
Summary and Future Directions
Nipah virus remains a major threat to public health and animal agriculture across its endemic range. Recent advances in structural biology, vaccine design, and antiviral development have accelerated progress toward medical countermeasures. However, sustained investment in bat ecology, surveillance infrastructure, and community engagement is needed to prevent and contain future spillovers. The development of cross-protective vaccines effective against all henipaviruses is a key research priority [6, 7]. Academic and governmental collaborations, such as the Henipavirus Preparedness Network, are essential for global health security [39].
References
[1] Magklara EP, Kkirgia M, Tsantes AG, et al. The Silent Spillover Threat: Nipah Virus Epidemiology, Pathogenesis, Clinical Manifestations, and Advances in Therapeutics and Vaccine Development. Microorganisms. 2026. PubMed ID 42197493.
[2] Apoorva, Singh SK. The Nipah virus threat in India: Epidemiological trends, risk drivers, and lessons for pandemic preparedness. PLoS Pathog. 2026. PubMed ID 42160364.
[3] Nelwan EJ. Current Situation and Global Perspective of Nipah Virus. Acta Med Indones. 2026. PubMed ID 41978305.
[4] Halpin K, Gómez Román R. Three decades of discovery: An overview of Hendra virus, the original Henipavirus. PLoS Negl Trop Dis. 2026. PubMed ID 41894354.
[5] Haas GD, Escaffre O, Reis RA, et al. De novo recovery of Ghana virus, an African bat Henipavirus, reveals differential tropism and attenuated pathogenicity compared to Nipah virus. Cell Rep. 2026. PubMed ID 41824449.
[6] Wang X, Zhang W. Henipaviruses at the threshold: preparedness in the era of recurrent spillover. Emerg Microbes Infect. 2026. PubMed ID 42261208.
[7] Tee KK, Xia X. Strengthening preparedness and response to emerging henipavirus diversity. Front Cell Infect Microbiol. 2026. PubMed ID 41822329.
[8] Hawkins TÉ, Calvaresi V, Burnap SA, et al. An Evolutionary Distinct Nipah Virus N-Glycosylation Site Provides Stability for Receptor Engagement. Mol Cell Proteomics. 2026. PubMed ID 41713789.
[9] Jayachandran RB, Quignon E, Renner M. Open and closed forms of assembled henipavirus nucleoprotein suggest structural basis of genome access. Sci Adv. 2026. PubMed ID 42127178.
[10] Larsen BB, Harari S, Gen R, et al. Functional and antigenic constraints on the Nipah virus fusion protein. Proc Natl Acad Sci U S A. 2026. PubMed ID 41650235.
[11] Ye C, Ma X, Ke X, et al. Nipah virus matrix protein promotes NF-κB activation by targeting multiple signaling modulators. J Virol. 2026. PubMed ID 42165681.
[12] Hao H, Chen Z, Zhang F, et al. NSUN2‑mediated epitranscriptomic and ubiquitin modulation of Nipah virus matrix protein reveals a dual-targeting antiviral strategy. Protein Cell. 2026. PubMed ID 41849232.
[13] Fenton KA, Turcinovic J, Prasad AN, et al. Progression of nipah virus infection in the African green monkey: Role of macrophages and dendritic cells in early virus spread. iScience. 2026. PubMed ID 42181233.
[14] Chowdhury KIA, Abdulla F, Shafique SMZ, et al. Social Media Promotion of Raw Date Palm Sap and Emerging Nipah Virus Transmission Risk in Bangladesh: Descriptive Analysis of Multisource Data. JMIR Form Res. 2026. PubMed ID 41926155.
[15] Li H, Yuan F, Yao Y, et al. Ecological vaccination: A strategy to prevent zoonotic spillover from bats. Sci Adv. 2026. PubMed ID 41811941.
[16] Pan K, Guo Z, Yuan Z, et al. Superspreading potential of Nipah virus disease despite self-limited human-to-human transmission in community. Int J Infect Dis. 2026. PubMed ID 41935612.
[17] Sorvillo TE, Davies KA, Welch SR, et al. Distinct respiratory and neurological disease phenotypes in lethal Nipah virus Malaysia versus Bangladesh infection in IFNAR knockout mice. Antiviral Res. 2026. PubMed ID 42035922.
[18] Rahman MM, Rahman S, Rahim S, et al. Mapping the geodispersal and evolutionary dynamics of regional Nipah virus strain in Bangladesh. Microbiol Spectr. 2026. PubMed ID 41817188.
[19] Escaffre O, Pearson ML, Juelich TL, et al. Efficacy of the nucleoside analog 4'-Fluorouridine against Nipah virus in the Syrian hamster model. PLoS Pathog. 2026. PubMed ID 41931570.
[20] Lane TR, Escaffre O, Zhang L, et al. Repurposing Clinical Candidates for Nipah and Hendra Viruses. ACS Infect Dis. 2026. PubMed ID 42052926.
[21] Voigt TB, Ghosh N, Rosen BC, et al. Heterologous Sequential mRNA Vaccination of Indian Rhesus Macaques Elicits Broad Binding and Neutralizing Antibody Responses Against Diverse Henipaviruses. Viruses. 2026. PubMed ID 42198690.
[22] Wälzlein JH, Reusch S, Ospina-Garcia J, et al. Human airway organoids as a versatile model to study BSL-4 virus replication and pathogenesis. Sci Rep. 2026. PubMed ID 41896609.
[23] Scotto G, Fazio V, Moula AM, et al. Nipah Virus Encephalitis: Pathogenetic Aspects and Current Therapeutic Strategies. Pathogens. 2026. PubMed ID 42075770.
[24] Guzmán-Solís AA, Ouizougun-Oubari M, Escaffre O, et al. A cocktail of human mAbs targeting the henipavirus fusion and receptor binding proteins provides cross-species neutralization. Sci Transl Med. 2026. PubMed ID 42268934.
[25] Mishra S, Kumar V, Kaur G, et al. Comparative immunogenicity of monomeric and tetrameric Nipah virus G glycoprotein-based vaccine candidates demonstrate robust antibody responses in both forms. Vaccine. 2026. PubMed ID 42107904.
[26] Ting LJ, Tan XL, Tiong V, et al. Sustained antibody response to a linear epitope of Nipah virus fusion protein in human survivor serum samples. Trop Biomed. 2026. PubMed ID 42126894.
[27] Chen M, Zhang X, Yao Y, et al. Complete protection against lethal Nipah virus challenge by intranasal vaccination with bacteriophage T4 coupled with Nipah virus G or F protein. Vaccine. 2026. PubMed ID 42140090.
[28] Ploquin A, Mason RD, Holman LA, et al. A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial. Nat Med. 2026. PubMed ID 41820674.
[29] Pigeaud DD, Amaya M, Borisevich V, et al. Analysis of Recombinant Cedar Virus Infection and Cross-Protection Against Related Henipaviruses in African Green Monkeys. Viruses. 2026. PubMed ID 41902200.
[30] Nguyen PV, Kimbro J, Ahmed K, et al. Nipah virus molecular detection from whole blood and respiratory swabs in a rapid field-ready protocol. J Clin Virol. 2026. PubMed ID 41865730.
[31] Zhang H, Cui C, Wang X, et al. Development of a one-pot RT-RAA/CRISPR-Cas13a assay for rapid genotyping of Nipah virus in pigs. Diagn Microbiol Infect Dis. 2026. PubMed ID 41713039.
[32] Hetrick B, Nakka SS, Yu D, et al. Development of a novel hybrid alphavirus-Nipah virus pseudovirion for rapid quantification of vaccine-induced neutralization antibodies. Emerg Microbes Infect. 2026. PubMed ID 42060533.
[33] Silva-Ayala D, Griffiths A. Validation of Chemical Inactivation Protocols for Henipavirus-Infected Tissue Samples. Viruses. 2026. PubMed ID 41600845.
[34] Rehman F, Mirza M. "Nipah virus: An overlooked threat and the promise of monoclonal antibody therapy". Diagn Microbiol Infect Dis. 2026. PubMed ID 41830685.
[35] Cortes-Azuero O, Vegvari C, Sutcliffe E, et al. Modeling optimal deployment strategies for Nipah vaccines and monoclonal antibodies. Vaccine. 2026. PubMed ID 42119335.
[36] Clayton E, Amaya M, Nguyen D, et al. Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection. J Gen Virol. 2026. PubMed ID 41649863.
[37] Dassanayake MK, Khoo TJ, Chong CH, et al. Predicted antiviral potential of phytochemicals prolific in Cleistanthus bracteosus Jabl. and essential oils of Artemisia scoparia and Thuja orientalis against Nipah virus and Human metapneumovirus: An AI-driven in-silico study. PLoS One. 2026. PubMed ID 41915655.
[38] Wong LP, Megat Hashim MMAA, Huang Z, et al. Navigating acceptance: challenges and barriers to Nipah virus vaccine uptake in Malaysia's muslim-majority context. Expert Rev Vaccines. 2026. PubMed ID 42132825.
[39] Halpin K, Román RG, de Wit E, et al. Integrating Prevention and Response at the Crossroads of Henipavirus Preparedness, Hendra@30 Conference, 2024. Emerg Infect Dis. 2026. PubMed ID 41612571.
[40] Gurajala S, Gurajala SS. Nipah Virus in Focus: A Comprehensive Review of the Pathogenesis, Epidemiological Patterns, Diagnostic Advances, and Future Public Health Strategies. Cureus. 2026. PubMed ID 41869112.
[41] Haque Z, Adan MMY, Zulfiker MS, et al. Bifurcations and optimal control in Nipah virus epidemiology. PLoS One. 2026. PubMed ID 41811821.
[42] Esmaeeli S. Nipah virus: An immunological wake-up call for global health systems. Immunol Lett. 2026. PubMed ID 41802635.